Boston Scientific's SEISMIQ Catheter Trial Exceeds Goals, Meets Safety & Effectiveness Endpoints
BSX is trading near its 52-week low of $52.52 (6.9% above the low).
Summary
Boston Scientific announced that its FRACTURE IDE Trial for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter successfully met both primary safety and effectiveness endpoints. The trial reported an impressive 93.3% freedom from Major Adverse Cardiac Events (MACE) at 30 days, surpassing its pre-defined performance goal. This positive clinical outcome for a specific product strengthens the company's cardiovascular portfolio and supports its competitive position in the intravascular lithotripsy market. For a large-cap medical device company like Boston Scientific, this represents a solid operational win, though it is an incremental positive development rather than a transformative event compared to the recent multi-billion dollar capital allocation news.
At the time of this announcement, BSX was trading at $56.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $83.1B. The 52-week trading range was $52.52 to $109.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.